article thumbnail

Open Targets Platform 23.12 has been released!

The Open Targets Blog

Introducing pharmacogenetics data to the Platform This release introduces a new datasource to the Platform: the pharmacogenetics widget will incorporate data about the impact of human genetic variation on drug responses. You can find this data on the target and drug profile pages.

article thumbnail

A personal touch: the role of bioprinting in drug discovery

Drug Discovery World

The company hopes that through its technology, academics, life science industries and pharma industries can test and develop more personalised treatments for intricate tissue engineering and cell therapy, such as repairing damaged tissue, replacing lost biological functions, localised therapeutic solutions and complex drug formulations. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Diaceutics Launches World’s First Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

The Pharma Data

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). There is a better way to get every patient the treatment they deserve. We believe that DXRX is that way.

article thumbnail

The use-case for NGS

Drug Discovery World

We can use NGS to better understand so-called “pharmacogenetics” so that we can predict how an individual may respond to a given treatment. Two different people could have the same type of cancer, but their tumour’s genetics could be ever so slightly different, but different enough that the treatment response is completely different.